STING1 and neoplasm: By contrast, immunostimulatory agents such as STING agonists can stimulate complex antitumor immunological programs that may be more dependent on immunological variables (e.g., neoantigen load, immune status of the TME) than on the efficiency of drug accumulation in tumor tissue or delivery to cancer cells.